 |
12 Diseases |  |
138 Trials |
|
138 Trials |  |
3994 News |  |
| «12...1920212223242526272829...3940» |
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Remodel: A Mechanistic Trial Evaluating the Effects of Semaglutide on the Kidneys In People With Type 2 Diabetes and Chronic Kidney Disease (Mini-Orals Hall) - May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_1219;
P3
The trial will provide valuable mechanistic insights on the use of OW semaglutide in people with T2D and CKD and may stimulate the development of a precision medicine approach to the management of such individuals. In addition, REMODEL will complement the findings of the FLOW trial.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
REAL-WORLD USE OF ONCE-WEEKLY SEMAGLUTIDE BY BASELINE ESTIMATED GLOMERULAR FILTRATION RATE – A POST HOC ANALYSIS OF POOLED DATA FROM THE SURE STUDIES (CANADA, DENMARK/SWEDEN, SWITZERLAND AND UNITED KINGDOM) (Virtual Hall 1) - May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_608;
CONCLUSION OW semaglutide provided clinically relevant glycaemic control and BW improvements, and was well tolerated, in patients with varying degrees of kidney impairment at treatment initiation in a real-world setting. These findings support semaglutide use in routine clinical practice regardless of patients’ kidney function.
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
BASELINE CHARACTERISTICS OF THE FLOW TRIAL POPULATION: KIDNEY OUTCOMES TRIAL WITH ONCE-WEEKLY SEMAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (Virtual Hall 1) - May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_607;
P3
According to Kidney Disease: Improving Global Outcomes categories, 24.8% of subjects were classified as high risk and 68.2% of subjects were classified as very high risk for CKD progression (Figure 1 ). CONCLUSION The FLOW trial will evaluate the efficacy and safety of semaglutide on kidney outcomes in subjects with T2D and high risk of kidney disease progression, a group for which additional therapies are urgently required.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Yes, there is a workaround, but it requires a fair amount of finessing with Ozempic => Wegovy. Happy to walk you through it if you message me. (Twitter) - May 5, 2022
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Wegovy supply chain problems hindering my use of it @novonordisk (Twitter) - May 5, 2022
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
@Novartis @NovartisScience @NovartisNews @NovartisGH How can you have NO Ozempic diabetes medication in Australia . What a disgrace (Twitter) - May 5, 2022
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
I'm on Ozempic as well (Twitter) - May 3, 2022
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
I’m down 70 lbs on wegovy. It’s literally retrained my brain about food. #wegovy #weightloss (Twitter) - Apr 30, 2022
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
And perhaps where Wegovy was priced is part of the problem (Twitter) - Apr 29, 2022
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: Hi Neil, Our partner program works with many doctors in the US to help their patients SAVE UP TO 90% on medication (such as Ozempic). It's A No-Cost Membership. For more information, visit: https://t.co/euXyHkzERq (Twitter) - Apr 26, 2022
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk
Journal: Long-acting amylin analogues for the management of obesity. (Pubmed Central) - Apr 26, 2022
CONCLUSION The FLOW trial will evaluate the efficacy and safety of semaglutide on kidney outcomes in subjects with T2D and high risk of kidney disease progression, a group for which additional therapies are urgently required. Long-acting amylin analogues have emerged as a possible pharmacotherapy against obesity, but more studies are needed to support the utility and long-term effects of this strategy in relevant populations.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial initiation date: SOCRATES-AF: Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients (clinicaltrials.gov) - Apr 26, 2022
P3, N=100, Not yet recruiting, Sponsor: Axel Brandes
Long-acting amylin analogues have emerged as a possible pharmacotherapy against obesity, but more studies are needed to support the utility and long-term effects of this strategy in relevant populations. Initiation date: Oct 2021 --> Oct 2022
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
P3 data, Journal: Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. (Pubmed Central) - Apr 22, 2022
P3
Initiation date: Oct 2021 --> Oct 2022 Adults from east Asia with obesity, with or without type 2 diabetes, given semaglutide 2·4 mg once a week had superior and clinically meaningful reductions in bodyweight, and greater reductions in abdominal visceral fat area compared with placebo, representing a promising treatment option for weight management in this population.
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: 🔆 1 year after withdrawal of once-weekly 💉 semaglutide 2.4 mg, patients regained two-thirds of prior weight loss. 🔆 Obesity requires aggressive & persistent treatment for durable success. Not easy! @ASMBS @EASOobesity @DrRobertKushner @ProfBatterhamMD https://t.co/8TPgC8Aebu (Twitter) - Apr 21, 2022
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Journal: An indirect treatment comparison of semaglutide 2.0 mg versus dulaglutide 3.0 mg and 4.5 mg using multilevel network meta-regression. (Pubmed Central) - Apr 21, 2022
This ITC demonstrated significantly greater reductions from baseline in HbA1c and body weight with semaglutide 2.0 mg vs dulaglutide 3.0 mg and 4.5 mg. The findings of this study provide important comparative effectiveness information until randomized head-to-head studies become available.
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Entrepreneurial spirit? Getting the itch? How about obesity medicine practice with a unique combination of surgical/medical tx options? With the advancements in medications (such as Wegovy), we're just scratching the surface of what obesity medicine will look like in 10 yrs. (Twitter) - Apr 20, 2022
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Bydureon (exenatide XR once-weekly) / AstraZeneca
Review, Journal: Exenatide Once Weekly for Management of Type 2 Diabetes: A Review. (Pubmed Central) - Apr 19, 2022
Furthermore, exenatide QW has been shown to be inferior to liraglutide and semaglutide with respect to HbA1c or body weight reduction in the head-to-head trials...On the other hand, exenatide QW is now expected to be a treatment option for children with T2DM or patients with Parkinson's disease. This review provides an overview of the current evidence regarding the clinical efficacy and safety of exenatide QW and discusses the current perspectives on exenatide QW for treatment of T2DM.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Review, Journal: Benefits of weight loss of 10% or more in patients with overweight or obesity: A review. (Pubmed Central) - Apr 15, 2022
Overall, large weight loss has a major beneficial impact on overweight- and obesity-related complications. Large weight loss should be the main treatment target when modest weight loss has had insufficient effects on obesity-related complications and for patients with severe obesity.
- | Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population. (Pubmed Central) - Apr 14, 2022
Large weight loss should be the main treatment target when modest weight loss has had insufficient effects on obesity-related complications and for patients with severe obesity. The results of this study indicate no difference between liraglutide and semaglutide in terms of A1c-lowering potential, but it provides insights into key considerations for the Veteran population.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
.@THR @Variety @CDCDiabetes @novonordisk @Dia_betesType2 @diabetesmanag How does it compare to Ozempic? (Twitter) - Apr 14, 2022
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Retrospective data, Journal, Real-world evidence: Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. (Pubmed Central) - Apr 13, 2022
P=N/A
The results of this study indicate no difference between liraglutide and semaglutide in terms of A1c-lowering potential, but it provides insights into key considerations for the Veteran population. In this pooled analysis, patients with T2D initiating OW semaglutide showed significant improvements from baseline to EOS in HbA and BW across various baseline subgroups, including patients previously treated with a GLP-1RA other than semaglutide, supporting OW semaglutide use in clinical practice.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Now, if they were forced to cover WeGovy at $1500 per month indefinitely —I bet they would be much more interested in covering bariatric surgery. 😔 (Twitter) - Apr 13, 2022
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study. (Pubmed Central) - Apr 12, 2022
In this pooled analysis, patients with T2D initiating OW semaglutide showed significant improvements from baseline to EOS in HbA and BW across various baseline subgroups, including patients previously treated with a GLP-1RA other than semaglutide, supporting OW semaglutide use in clinical practice. Switching from once-daily liraglutide to once-weekly semaglutide led to improvements in both clinical measures of glycemic control and patient-reported satisfaction.
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial initiation date: Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity (clinicaltrials.gov) - Apr 7, 2022
P3, N=150, Not yet recruiting, Sponsor: Novo Nordisk A/S
Switching from once-daily liraglutide to once-weekly semaglutide led to improvements in both clinical measures of glycemic control and patient-reported satisfaction. Initiation date: Apr 2022 --> Aug 2022
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
Review, Journal: GLP-1 physiology informs the pharmacotherapy of obesity. (Pubmed Central) - Apr 5, 2022
GLP1RA may also be effective in conditions associated with obesity, such as cardiovascular disease and non-alcoholic steatohepatitis (NASH). Progressive improvements in the efficacy of GLP1RA suggest that GLP-1-based therapies may soon rival bariatric surgery as viable options for the treatment of obesity and its complications.
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Trial initiation date: SMART: SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes (clinicaltrials.gov) - Apr 5, 2022
P3, N=98, Enrolling by invitation, Sponsor: University Medical Center Groningen
Progressive improvements in the efficacy of GLP1RA suggest that GLP-1-based therapies may soon rival bariatric surgery as viable options for the treatment of obesity and its complications. Not yet recruiting --> Enrolling by invitation | Initiation date: Sep 2021 --> Mar 2022
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial initiation date, Trial primary completion date: Latino Semaglutide Study (clinicaltrials.gov) - Apr 5, 2022
P3, N=100, Not yet recruiting, Sponsor: Loma Linda University
Not yet recruiting --> Enrolling by invitation | Initiation date: Sep 2021 --> Mar 2022 Trial completion date: Aug 2022 --> Aug 2023 | Initiation date: Feb 2022 --> Sep 2022 | Trial primary completion date: Aug 2022 --> Aug 2023
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Journal, Adverse events: Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. (Pubmed Central) - Apr 1, 2022
GI AEs were more common with semaglutide 2.4 mg than placebo, but typically mild-to-moderate and transient. Semaglutide-induced WL was largely independent of GI AEs.
- || Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Journal: Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials. (Pubmed Central) - Apr 1, 2022
In PIONEER 9 and 10, patients were randomized to once-daily oral semaglutide (3, 7 or 14 mg) or a comparator (placebo or once-daily subcutaneous liraglutide 0.9 mg [PIONEER 9]; once-weekly subcutaneous dulaglutide 0.75 mg [PIONEER 10]) for 52 weeks, with 5 weeks' follow-up...There was generally a higher rate of premature trial product discontinuation due to AEs in the older age group. These results indicate that oral semaglutide is efficacious in Japanese patients irrespective of age.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: The importance of addressing multiple risk markers in type 2 diabetes: results from the LEADER and SUSTAIN 6 trials. (Pubmed Central) - Apr 1, 2022
The nephropathy risk decreased with improvement in more risk markers. These findings stress the importance of multifactorial interventions targeting all risk markers.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Journal: A model-based simulation of glycemic control and body weight when switching from semaglutide to 3.0 and 4.5 mg doses of once-weekly dulaglutide. (Pubmed Central) - Apr 1, 2022
These findings stress the importance of multifactorial interventions targeting all risk markers. Switching from semaglutide 0.5 mg to dulaglutide 3.0 or 4.5 mg with dose escalation potentially yields additional HbA1c and weight reductions; switching from semaglutide 1.0 mg to dulaglutide 4.5 mg may enhance weight loss.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Retrospective data, Review, Journal: Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis. (Pubmed Central) - Apr 1, 2022
Switching from semaglutide 0.5 mg to dulaglutide 3.0 or 4.5 mg with dose escalation potentially yields additional HbA1c and weight reductions; switching from semaglutide 1.0 mg to dulaglutide 4.5 mg may enhance weight loss. No abstract available
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P2/3 trial: Semaglutide for post-liver transplant obesity (EUDRACT) - Apr 1, 2022
P2/3, N=100, Not yet recruiting, Sponsor: Austin Health
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
NO ONE IS OFFERING ANY ASSISTANCE, I WAS ONCE TOLD, IF I DIDNT HAVE THE $1070.50 to pay for the Ozempic, too bad for me! (Twitter) - Mar 31, 2022
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada. (Pubmed Central) - Mar 31, 2022
The survey suggests that physicians are satisfied with the OW semaglutide clinical effects. Video Abstract: http://links.lww.com/CAEN/A34.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: MitoSema: Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes (clinicaltrials.gov) - Mar 31, 2022
P4, N=50, Recruiting, Sponsor: Kirsi Pietil
Video Abstract: http://links.lww.com/CAEN/A34. Not yet recruiting --> Recruiting | Trial completion date: Aug 2024 --> Aug 2025 | Initiation date: May 2021 --> Feb 2022 | Trial primary completion date: Aug 2024 --> Aug 2025
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P4 trial: Semaglutide Use in Elderly Obese Patients (clinicaltrials.gov) - Mar 31, 2022
P4, N=16, Not yet recruiting, Sponsor: State University of New York at Buffalo
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P4 trial: Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes (clinicaltrials.gov) - Mar 31, 2022
P4, N=90, Recruiting, Sponsor: University of Erlangen-N
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
FDA event: Interesting to see the transition of dosing and dose steps - U.S. FDA approves Novo Nordisk's diabetes drug Ozempic in 2 mg dose https://t.co/bAi6U7OFg8 @DLBHATTMD @AskDrShashank @drkevinfernando @AmarPut @drpatrickholmes @dr_amritlamba (Twitter) - Mar 31, 2022
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
FDA event: Very exciting! The 2mg version of semaglutide (Ozempic) just got FDA approved! (Twitter) - Mar 29, 2022
- || Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal: Wegovy (semaglutide): a new weight loss drug for chronic weight management. (Pubmed Central) - Mar 29, 2022
Trial data and other pertinent articles were obtained via database search through the US National Library of Medicine Clinical Trials and the National Center for Biotechnology Information. All three clinical trials demonstrated that semaglutide (injected or oral) has superior efficacy compared with placebo and other antidiabetic medications in weight reduction, which led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss.
- |||| cotadutide (MEDI0382) / AstraZeneca
Trial completion: A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Mar 29, 2022
P2b, N=247, Completed, Sponsor: AstraZeneca
All three clinical trials demonstrated that semaglutide (injected or oral) has superior efficacy compared with placebo and other antidiabetic medications in weight reduction, which led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss. Active, not recruiting --> Completed
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
FDA event: U.S. FDA approves Novo Nordisk's diabetes drug Ozempic in 2 mg dose https://t.co/eLOiRGY37e (Twitter) - Mar 28, 2022
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial completion date: Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology (clinicaltrials.gov) - Mar 28, 2022
P2, N=200, Active, not recruiting, Sponsor: Region Skane
Active, not recruiting --> Completed Trial completion date: Dec 2021 --> Dec 2022
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Journal, Real-world evidence: Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: real-world data from a diabetes out-patient clinic. (Pubmed Central) - Mar 25, 2022
Trial completion date: Dec 2021 --> Dec 2022 We observed effects of semaglutide once weekly on HbA1c and body weight comparable to the effects observed in clinical studies with fewer persons in our cohort receiving maximum dose of semaglutide.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Retrospective data, Journal: Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. (Pubmed Central) - Mar 24, 2022
We observed effects of semaglutide once weekly on HbA1c and body weight comparable to the effects observed in clinical studies with fewer persons in our cohort receiving maximum dose of semaglutide. Among adults with overweight or obesity, once-weekly semaglutide could result in clinically meaningful weight loss, which was a promising therapy for treating overweight or obesity.
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial primary completion date, HEOR, Real-world evidence, Real-world: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial (clinicaltrials.gov) - Mar 24, 2022
P4, N=1387, Active, not recruiting, Sponsor: Novo Nordisk A/S
Among adults with overweight or obesity, once-weekly semaglutide could result in clinically meaningful weight loss, which was a promising therapy for treating overweight or obesity. Trial primary completion date: Jan 2022 --> Jun 2022
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: STEP 10: Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes (clinicaltrials.gov) - Mar 23, 2022
P3, N=201, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jan 2022 --> Jun 2022 Recruiting --> Active, not recruiting
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, warfarin / Generic mfg.
Clinical: 2/2...the label says "Discontinue WEGOVY if the patient cannot tolerate the 2.4 mg dose"...so we are not finding the right dose for the patient here, just upping it to the max...a big difference. Insulin/anaethetic agents/warfarin have wide dose ranges ... because we need them! (Twitter) - Mar 22, 2022
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany (Poster area 1) - Mar 22, 2022 - Abstract #DDG2022DDG_537;
A total of 39 documented hypoglycaemic episodes were reported, none were severe. In routine clinical practice in Germany, patients with T2D treated with OW semaglutide experienced clinically significant improvements in HbA1c, BW and WC, supporting real-world use.